Pharma makers pull MS drug from worldwide market
In a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis after reports of serious brain inflammation in patients.
In a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis (MS) after reports of serious brain inflammation in patients.
AbbVie and Biogen voluntarily recalled daclizumab (Zinbryta) worldwide for relapsing MS because “the companies believe that characterizing the complex and evolving benefit/risk profile of Zinbryta will not be possible going forward, given the limited number of patients being treated,” the two companies said in a statement.
Related: First progressive MS drug carries high price tag
The European Medicines Agency (EMA) called for an urgent review of the drug after 7 patients in Germany and 1 patient in Spain experienced encephalitis and/or meningoencephalitis (brain inflammation).
More than 8,000 patients around the world have received Zinbryta, according to the EMA. It is sold in the European Union, the US, Switzerland, Canada, and Australia.
Related: New warning on antibiotic for heart disease patients
“Biogen believes the voluntary worldwide withdrawal of Zinbryta….is in the best interest of patients,” said Alfred Sandrock, MD, PhD, executive vice president and chief medical officer at Biogen, in the statement. “Biogen and AbbVie continue to prioritize patient safety and the care of multiple sclerosis patients worldwide.”
Patients who are currently being treated with Zinbryta should contact their healthcare provider if they have any questions or concerns, the two companies said.
While daclizumab was approved by FDA in 2016 to treat MS, the agency warned that the drug could cause "serious or life-threatening liver damage" and "serious immune system disorders,” CNN reported.
Read more: FDA issues warning over marijuana products claiming cancer cure
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
